

BIOGRAPHICAL SKETCH

NAME Bittencourt, Henrique Neves da Silva	POSITION TITLE MD PhD		
eRA COMMONS USER NAME (credential, e.g., agency login)			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY
School of Medicine – UFRGS – Porto Alegre - Brazil	MD	1985-1990	
Hospital de Clinicas de Porto Alegre – Porto Alegre – Brazil	Residency	1991-1992	Internal Medicine
Hospital de Clinicas de Porto Alegre – Porto Alegre – Brazil	Residency	1993-1995	Hematology
School of Medicine – UFRGS – Porto Alegre – Brazil	MSc	1995-1998	Hematology -Acute Leukemia
Saint Louis Hospital – Paris - France	Fellowship	1998-2000	Stem Cell Transplantation
School of Medicine – UFRGS – Porto Alegre – Brazil	PhD	1998-2002	Stem Cell Transplantation

A. Personal Statement

Associate Clinical Professor, University of Montreal, since 2010. Member of the Hematology-Oncology Division – CHU Sainte-Justine. Member of the Cell Therapy Program and Director of the Relapse Leukemia and Myeloid Malignancies Programs. Clinical Researcher of the Immune Disorders and Cancer Axis of the CHU Sainte-Justine Research Center.

Initial training on Internal Medicine and Hematology at the University Hospital from Federal University of Rio Grande do Sul. Fellowship on Hematopoietic Stem Cell Transplantation at Saint-Louis Hospital (Paris, France). PhD degree in 2002 (Influence of CD34+ cell dose on the different outcomes after allogeneic bone marrow transplantation).

Main interest on research are: Hematopoietic stem cell transplantation (conditioning regimens; short and long-term complications; Graft-vs-Host (GVH) disease and graft-vs-Leukemia (GVL) effect); immunotherapy (including CAR-T), treatment of acute, chronic, de novo and relapsed leukemia, early (Phase I-II) clinical trials.

I'm the center PI for TACL, EBMT and Eurocord studies; I'm also the center PI for COG and industry driven studies on hematopoietic stem cell transplantation, leukemia (AML, CML and relapsed ALL/AML), including immunotherapy with CAR-T cells for relapsed ALL. I'm also conducting at this very moment Phase I studies and also retrospective studies.

B. Positions and Honors

2000 - 2004	Director Stem Cell Transplantation Program - Hospital Santa Casa de Misericordia de Porto Alegre - Porto Alegre - Brazil
2000 - 2004	Attending Physician (Hematologist - Stem Cell Transplantation Program) – Hospital de Clinicas de Porto Alegre - Porto Alegre - Brazil
2004 - 2009	Director Stem Cell Transplantation Program - Hospital das Clinicas da UFMG (University Hospital)- Belo Horizonte – Brazil
2005 – 2010	Assistant Professor – School of Medicine – Universidade Federal de Minas Gerais (UFMG)
2009- 2009	Head – Hematology and Oncology Division - Hospital das Clinicas da UFMG (University Hospital)- Belo Horizonte – Brazil

2010 - ongoing Associate Professor – Department of Pediatrics - University of Montreal – Montreal – Qc - Canada

2010 - ongoing Attending physician (Cell Therapy Program) - Hematology/Oncology Division - Sainte-Justine Hospital (CHU Sainte-Justine) - Montreal – Qc – Canada

2010- ongoing Member – Hematology/Oncology Program - Hematology/Oncology Division - CHU Sainte-Justine

2010 - ongoing Director – Relapse Leukemia Program – Hematology/Oncology Division - CHU Sainte-Justine

2010 - ongoing Co-Director – Myeloid Malignancies – Hematology/Oncology Division - CHU Sainte-Justine

2013 - ongoing Associate researcher - Immune Diseases and Cancer - Sainte-Justine University Hospital Research Center - Montreal – Qc - Canada.

2013 - ongoing Member of the Steering Committee – Canadian Registry on Bone and Marrow Transplantation.

2014 - ongoing Co-Director - Hematopoietic Stem Cell Transplantation BioBank (BaCH)

2014 - ongoing Consulting for Jazz Pharmaceuticals

2014 Consulting for Seattle Genetics

2016 - 2017 Member - Program Executive Committee – Terry Fox Precision Oncology for Young People Program (PROFYLE)

2016 - 2017 Co-Chair – Clinical Trial Node – Terry Fox Precision Oncology for Young People Program (PROFYLE)

2016 - Ongoing Manager Committee – Hematology-Oncology and Immunology Clinical Research Unit

2017 Consulting for Amgen Canada

2017 - ongoing Consulting for Novartis Oncology

2018 - Ongoing Member of the Cancer in Young People in Canada (CYP-C) PI Council.

2018 - ongoing Member - Area of Focused Competence (AFC) Working Group for Hematopoietic Stem Cell Transplantation and Cell Therapy – Royal College of Physicians and Surgeons of Canada.

2019 – ongoing Medical Director – Cellular Therapy Laboratory – CHU Sainte-Justine

2019 – ongoing Medical manager – Early Phase Clinical Research Unit in Hemato-Oncology – CHU Sainte-Justine

C. Publications

1. Marc Ansari, Kateryna Petrykey, Mohamed Aziz Rezgui, Veronica Del Vecchio, Jacques Cortyl, Reginald-Olivier Ralph, Tiago Nava, Patrick Beaulieu, Pascal St-Onge, Simona Jurkovic Mlakar, Patricia Huezo-Diaz Curtis, Chakradhara Rao S Uppugunduri, Laurence Lesne, Yves Théoret, Yves Chalandon, Imke H Bartelink, Jaap-Jan Boelens, Robbert G M Bredius, Jean-Hugues Dalle, Victor Lewis, Bill S Kangaroo, Christina Peters, Daniel Sinnett, **Henrique Bittencourt**, Maja Krajinovic. Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 2019 Nov 29[Online ahead of print].
2. Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, **Bittencourt H**, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J, Harris AC. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. *Lancet Oncol.* 2019 Dec;20(12):1710-1718. PubMed PMID: 31606419.
3. Pincez T, Landry JR, Roussy M, Jouan L, Bilodeau M, Laramée L, Couture F, Sinnett D, Gendron P, Hébert J, Oligny L, Rouette A, Tran TH, Wilhelm BT, **Bittencourt H**, Cellot S. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia. *Genes Chromosomes Cancer.* 2019 Sep 12;. doi: 10.1002/gcc.22808. [Epub ahead of print] PubMed PMID: 31515871.

4. Athale U, Hijjiya N, Patterson BC, Bergsagel J, Andolina JR, **Bittencourt H**, Schultz KR, Burke MJ, Redell MS, Kolb EA, Johnston DL. Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. *Pediatr Blood Cancer*. 2019 Sep;66(9):e27827. doi: 10.1002/pbc.27827. Epub 2019 Jun 10. Review. PubMed PMID: 31330093; PubMed Central PMCID: PMC6944522.
5. Mourad S, Bilodeau M, Roussy M, Laramée L, Boulianne L, Rouette A, Jouan L, Gendron P, Duval M, Teira P, Hébert J, **Bittencourt H**, Pastore Y, Landry JR, Cellot S. IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome. *Front Oncol*. 2019;9:772. doi: 10.3389/fonc.2019.00772. eCollection 2019. PubMed PMID: 31475115; PubMed Central PMCID: PMC6702516.
6. Cuvelier GDE, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, **Bittencourt H**, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savaşan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, West LJ, Pan B, Al-Hamarneh YN, Halevy A, Schultz KR. Benefits and challenges with diagnosing chronic and late acute GvHD in children using the NIH consensus criteria. *Blood*. 2019 May 1. pii: blood.2019000216. doi: 10.1182/blood.2019000216. [Epub ahead of print]
7. Khater F, Vairy S, Langlois S, Dumoucel S, Sontag T, St-Onge P, **Bittencourt H**, Dal Soglio D, Champagne J, Duval M, Leclerc JM, Laverdiere C, Tran TH, Patey N, Ellezam B, Perreault S, Piché N, Samson Y, Teira P, Jabado N, Michon B, Brossard J, Marzouki M, Cellot S, Sinnett D. Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. *JAMA Netw Open*. 2019 Apr 5;2(4):e192906. doi: 10.1001/jamanetworkopen.2019.2906.
8. Truong TH, Pole JD, **Bittencourt H**, Schechter T, Cuvelier GDE, Paulson K, Rayar M, Mitchell D, Schultz KR, O'Shea D, Barber R, Wall D, Sung L. Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. *Biol Blood Marrow Transplant*. 2019 Feb 12. pii: S1083-8791(19)30134-X. doi: 10.1016/j.bbmt.2019.02.009. [Epub ahead of print]
9. Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, **Bittencourt H**, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. *Nat Med*. 2018 Oct;24(10):1504-1506.
10. Vairy S, Lopes Garcia J, Teira P, **Bittencourt H**. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. *Drug Design, Development and Therapy*. In press 2018
11. Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, **Bittencourt H**, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. *Nat Med*. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1. PubMed PMID: 30275569.
12. Nava T, Kassir N, Rezgui MA, Uppugunduri CRS, Huezio-Diaz Curtis P, Duval M, Théoret Y, Daudt LE, Litalien C, Ansari M, Krajcinovic M, **Bittencourt H**. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. *Br J Clin Pharmacol*. 2018 Jul;84(7):1494-1504. doi: 10.1111/bcp.13566. Epub 2018 Apr 27. PubMed PMID: 29469189; PubMed Central PMCID: PMC6005620.

13. Roussy M, Bilodeau M, Jouan L, Tibout P, Laramée L, Lemyre E, Léveillé F, Tihy F, Cardin S, Sauvageau C, Couture F, Louis I, Choblet A, Patey N, Gendron P, Duval M, Teira P, Hébert J, Wilhelm BT, Choi JK, Gruber TA, **Bittencourt H**, Cellot S. NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. Genes Chromosomes Cancer. 2018 Jun;57(6):311-319. doi: 10.1002/gcc.22532. Epub 2018 Mar 28. PubMed PMID: 29427526.
14. Benadiba J, Ansari M, Krajinovic M, Vachon MF, Duval M, Teira P, Cellot S, **Bittencourt H**. Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children. PLoS One. 2018 Apr 2;13(4):e0193862. doi: 10.1371/journal.pone.0193862. eCollection 2018. PubMed PMID: 29608607; PubMed Central PMCID: PMC5880335.
15. Paviglianiti A, Dalle JH, Ayas M, Boelens JJ, Volt F, Iori AP, de Souza MP, Diaz MA, Michel G, Locatelli F, Jubert C, Yakoub-Agha I, **Bittencourt H**, Bertrand Y, Kenzey C, Tozatto Maio K, Hayashi H, Rocha V, Bader P, Gluckman E, Ruggeri A. Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biol Blood Marrow Transplant. 2018 Apr;24(4):799-805. doi: 10.1016/j.bbmt.2017.12.790. Epub 2017 Dec 27. PubMed PMID: 29288817.
16. Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, **Bittencourt H**, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018 Mar 15. doi: 10.1038/s41375-018-0094-0. [Epub ahead of print] PubMed PMID: 29728694.
17. Sun W, Triche T Jr, Malvar J, Gaynon P, Sposto R, Yang X, **Bittencourt H**, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, Cooper TM, Liang G. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. Blood. 2018 Mar 8;131(10):1145-1148. doi: 10.1182/blood-2017-09-803809. Epub 2018 Jan 16. PubMed PMID: 29339403; PubMed Central PMCID: PMC5863703.
18. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, **Bittencourt H**, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866. PubMed PMID: 29385370; PubMed Central PMCID: PMC5996391.
19. Huezo-Diaz Curtis P, Uppugunduri CRS, Muthukumaran J, Rezgui MA, Peters C, Bader P, Duval M, **Bittencourt H**, Krajinovic M, Ansari M. Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. Pharmacogenomics J. 2018 Jan;18(1):64-69. doi: 10.1038/tpj.2016.65. Epub 2016 Oct 25. PubMed PMID: 27779248; PubMed Central PMCID: PMC5817388.
20. McMahon J, Théorêt Y, Autmizguine J, **Bittencourt H**, Tapiéro B, Ovetchkine P. Posaconazole Plasma Monitoring in Immunocompromised Children. J Pediatric Infect Dis Soc. 2017 Nov 24;6(4):389-392. doi: 10.1093/jpids/piw087. PubMed PMID: 28186550.

21. Nava T, Rezgui MA, Uppugunduri CRS, Curtis PH, Théoret Y, Duval M, Daudt LE, Ansari M, Krajinovic M, **Bittencourt H**. GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Nov;23(11):1918-1924. doi: 10.1016/j.bbmt.2017.07.022. Epub 2017 Aug 12. PubMed PMID: 28807770.
22. Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L, Théoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, **Bittencourt H**, Krajinovic M. GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. *Oncotarget*. 2017 Aug 27;8(53):90852-90867. doi: 10.18632/oncotarget.20310. eCollection 2017 Oct 31. PubMed PMID: 29207608; PubMed Central PMCID: PMC5710889.
23. Legeay C, **Bittencourt H**, Haddad E, Spiesser-Robelet L, Thépot-Seegers V, Therrien R. A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population. *J Pediatr Pharmacol Ther*. 2017 Sep-Oct;22(5):369-374. doi: 10.5863/1551-6776-22.5.369. PubMed PMID: 29042839; PubMed Central PMCID: PMC5640305.
24. Page KM, Labopin M, Ruggeri A, Michel G, Diaz de Heredia C, O'Brien T, Picardi A, Ayas M, **Bittencourt H**, Vora AJ, Troy J, Bonfim C, Volt F, Gluckman E, Bader P, Kurtzberg J, Rocha V. Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1350-1358. doi: 10.1016/j.bbmt.2017.04.015. Epub 2017 Apr 21. PubMed PMID: 28438676; PubMed Central PMCID: PMC5569913.
25. Santiago R, Vairy S, Sinnott D, Krajinovic M, **Bittencourt H**. Novel therapy for childhood acute lymphoblastic leukemia. *Expert Opin Pharmacother*. 2017 Aug;18(11):1081-1099. doi: 10.1080/14656566.2017.1340938. Epub 2017 Jun 26. Review. PubMed PMID: 28608730.
26. Uppugunduri CRS, Storelli F, Mlakar V, Huezo-Diaz Curtis P, Rezgui A, Théorêt Y, Marino D, Doffey-Lazeyras F, Chalandon Y, Bader P, Daali Y, **Bittencourt H**, Krajinovic M, Ansari M. The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. *Front Pharmacol*. 2017 Jul 11;8:451. doi: 10.3389/fphar.2017.00451. eCollection 2017. PubMed PMID: 28744217; PubMed Central PMCID: PMC5504863.
27. Shekhovtsova Z, Bonfim C, Ruggeri A, Nichele S, Page K, AlSeraihy A, Barriga F, de Toledo Codina JS, Veys P, Boelens JJ, Mellgren K, **Bittencourt H**, O'Brien T, Shaw PJ, Chybicka A, Volt F, Giannotti F, Gluckman E, Kurtzberg J, Gennery AR, Rocha V; Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT, Federal University of Parana, Duke University Medical Center and Inborn Errors Working Party of the EBMT.. A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. *Haematologica*. 2017 Jun;102(6):1112-1119. doi: 10.3324/haematol.2016.158808. Epub 2017 Mar 2. PubMed PMID: 28255019; PubMed Central PMCID: PMC5451344.
28. Khater F, Lajoie M, Langlois S, Healy J, Cellot S, Richer C, Beaulieu P, St-Onge P, Saillour V, Minden M, Marzouki M, Krajinovic M, **Bittencourt H**, Sinnott D. KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia. *Blood*. 2017 Mar 23;129(12):1729-1732. doi: 10.1182/blood-2016-10-744219. Epub 2017 Jan 9. PubMed PMID: 28069604; PubMed Central PMCID: PMC5374844.
29. Resende CB, Rezende BM, Bernardes PT, Teixeira GM, Teixeira MM, Pinho V, **Bittencourt H**. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower

rate of acute GVHD, increased risk of cytomegalovirus reactivation. Braz J Med Biol Res. 2017 Feb 9;50(2):e5566. doi: 10.1590/1414-431X20165566. PubMed PMID: 28198910; PubMed Central PMCID: PMC5343562.

30. Cunha R, Zago MA, Querol S, Volt F, Ruggeri A, Sanz G, Pouthier F, Kogler G, Vicario JL, Bergamaschi P, Saccardi R, Lamas CH, Díaz-de-Heredia C, Michel G, **Bittencourt H**, Tavella M, Panepucci RA, Fernandes F, Pavan J, Gluckman E, Rocha V; Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Netcord and Faculdade de Medicina de Ribeirão Preto–Faculdade de Medicina de São Paulo, Universidade de São Paulo.. Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. Blood. 2017 Jan 26;129(4):525-532. doi: 10.1182/blood-2016-06-722249. Epub 2016 Nov 3. PubMed PMID: 27811020.
31. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, **Bittencourt H**, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktél S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov;3(11):e526-e536. doi: 10.1016/S2352-3026(16)30114-4. Epub 2016 Oct 13. PubMed PMID: 27746112; PubMed Central PMCID: PMC5159247.
32. Ceppi F, Duval M, Leclerc JM, Laverdiere C, Delva YL, Cellot S, Teira P, **Bittencourt H**. Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy. PLoS One. 2016 Sep 15;11(9):e0160310. doi: 10.1371/journal.pone.0160310. eCollection 2016. PubMed PMID: 27632202; PubMed Central PMCID: PMC5025146.
33. Saccardi R, Tucunduva L, Ruggeri A, Ionescu I, Kogler G, Querol S, Grazzini G, Lecchi L, Nanni Costa A, Navarrete C, Pouthiers F, Larghero J, Regan D, Freeman T, **Bittencourt H**, Kenzey C, Labopin M, Baudoux E, Rocha V, Gluckman E. Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis. Transfusion. 2016 Aug;56(8):2021-9. doi: 10.1111/trf.13661. Epub 2016 May 31. PubMed PMID: 27245270.
34. Michel G, Cunha R, Ruggeri A, O'Brien TA, **Bittencourt H**, Dalle JH, Locatelli F, Iori AP, Mauad M, Oudin C, Giannotti F, Volt F, Gluckman E, Bader P, Rocha V. Unrelated cord blood transplantation for childhood acute myelogenous leukemia: The influence of cytogenetic risk group stratification. Leukemia. 2016 May;30(5):1180-3. doi: 10.1038/leu.2015.243. Epub 2015 Sep 15. PubMed PMID: 26369981.
35. Ansari M, Huezo-Diaz P, Rezgui MA, Marktél S, Duval M, **Bittencourt H**, Cappelli B, Krajinovic M. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. Bone Marrow Transplant. 2016 Mar;51(3):377-83. doi: 10.1038/bmt.2015.321. Epub 2015 Dec 21. PubMed PMID: 26691424; PubMed Central PMCID: PMC4777888.
36. Legeay C, Spiesser-Robelet L, **Bittencourt H**, Haddad E, Therrien R. Rapid Infusion of Rituximab in a Heterogenous Pediatric Population: Safety and Feasibility. J Pediatr Hematol Oncol. 2016 Jan;38(1):83-5. doi: 10.1097/MPH.0000000000000480. PubMed PMID: 26583612.
37. Teixeira GM, **Bittencourt H**, de Macedo AV, Martinho GH, Colosimo EA, Rezende SM. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country. PLoS One. 2015 Sep 22;10(9):e0137390. doi:

38. Sarem S, Nekka F, Barrière O, **Bittencourt H**, Duval M, Teira P, Haddad E, Théorêt Y, Lapeyraque AL, Litalien C. Limited sampling strategies for estimating intravenous and oral cyclosporine area under the curve in pediatric hematopoietic stem cell transplantation. Ther Drug Monit. 2015 Apr;37(2):198-205. doi: 10.1097/FTD.000000000000124. PubMed PMID: 25162214.
39. Ceppi F, Duval M, Teira P, Therrien R, Ovetchkine P, Mallette B, **Bittencourt H**. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease. J Pediatr Hematol Oncol. 2014 Jul;36(5):e319-21. doi: 10.1097/MPH.000000000000066. PubMed PMID: 24977404.
40. Uppugunduri CR, Rezgui MA, Diaz PH, Tyagi AK, Rousseau J, Daali Y, Duval M, **Bittencourt H**, Krajinovic M, Ansari M. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J. 2014 Jun;14(3):263-71. doi: 10.1038/tpj.2013.38. Epub 2013 Oct 29. PubMed PMID: 24165757.
41. Ruggeri A, Sanz G, **Bittencourt H**, Sanz J, Rambaldi A, Volt F, Yakoub-Agha I, Ribera JM, Mannone L, Sierra J, Mohty M, Solano C, Nabhan S, Arcese W, Gluckman E, Labopin M, Rocha V; Eurocord and Acute Leukemia Working Party of European Blood and Marrow Transplant Group.. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2014 Apr;28(4):779-86. doi: 10.1038/leu.2013.259. Epub 2013 Sep 5. PubMed PMID: 24005245.
42. Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, **Bittencourt H**; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit. 2014 Feb;36(1):93-9. doi: 10.1097/FTD.0b013e3182a04fc7. PubMed PMID: 24061446.
43. Kurtzberg J, Prockop S, Teira P, **Bittencourt H**, Lewis V, Chan KW, Horn B, Yu L, Talano JA, Nemecek E, Mills CR, Chaudhury S. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014 Feb;20(2):229-35. doi: 10.1016/j.bbmt.2013.11.001. Epub 2013 Nov 8. PubMed PMID: 24216185.
44. Cunha R, Loiseau P, Ruggeri A, Sanz G, Michel G, Iori AP, Socié G, Arcese W, Picardi A, Dias de Heredia C, Rio B, Locatelli F, O'Brien TA, Yakoub-Agha I, Angel Diaz M, Milpied N, **Bittencourt H**, Pedro Souza M, Aljurf M, Charron D, Boudjedir K, Labopin M, Gluckman E, Rocha V. Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. Bone Marrow Transplant. 2014 Jan;49(1):24-9. doi: 10.1038/bmt.2013.120. Epub 2013 Aug 19. Erratum in: Bone Marrow Transplant. 2014 Jun;49(6):864. Paolaiori, A [corrected to Iori, A P]. PubMed PMID: 23955634.
45. Locatelli F, Crotta A, Ruggeri A, Eapen M, Wagner JE, Macmillan ML, Zecca M, Kurtzberg J, Bonfim C, Vora A, Díaz de Heredia C, Teague L, Stein J, O'Brien TA, **Bittencourt H**, Madureira A, Strahm B, Peters C, Niemeyer C, Gluckman E, Rocha V. Analysis of risk factors influencing outcomes after cord blood

transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood. 2013 Sep 19;122(12):2135-41. doi: 10.1182/blood-2013-03-491589. Epub 2013 Aug 7. PubMed PMID: 23926304; PubMed Central PMCID: PMC3836039.

46. Ansari M, Uppugunduri CR, Ferrari-Lacraz S, **Bittencourt H**, Gummy-Pause F, Chalandon Y, Tiercy JM, Schechter T, Gassas A, Doyle JD, Dupuis L, Duval M, Krajinovic M, Villard J. The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children. PLoS One. 2013 Aug 19;8(8):e72141. doi: 10.1371/journal.pone.0072141. eCollection 2013. PubMed PMID: 23977232; PubMed Central PMCID: PMC3747133.
47. Ansari M, Rezgui MA, Théoret Y, Uppugunduri CR, Mezziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Przybyla C, Duval M, Champagne M, Peters C, **Bittencourt H**, Krajinovic M; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. Bone Marrow Transplant. 2013 Jul;48(7):939-46. doi: 10.1038/bmt.2012.265. Epub 2013 Jan 7. PubMed PMID: 23292236.
48. Robitaille N, Lacroix J, Alexandrov L, Clayton L, Cortier M, Schultz KR, **Bittencourt H**, Duval M. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial. Biol Blood Marrow Transplant. 2013 Mar;19(3):468-73. doi: 10.1016/j.bbmt.2012.12.002. Epub 2012 Dec 7. PubMed PMID: 23220014.
49. Ribeiro AF, Nobre V, Neuenschwander LC, Teixeira AL, Xavier SG, Paula FD, Teixeira MM, Teixeira JC, **Bittencourt H**. Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia. Braz J Med Biol Res. 2013 Feb;46(2):200-6. Epub 2013 Feb 1. PubMed PMID: 23369970; PubMed Central PMCID: PMC3854365.
50. Ruggeri A, Michel G, Dalle JH, Caniglia M, Locatelli F, Campos A, de Heredia CD, Mohty M, Hurtado JM, Bierings M, **Bittencourt H**, Mauad M, Purtill D, Cunha R, Kabbara N, Gluckman E, Labopin M, Peters C, Rocha V. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia. 2012 Dec;26(12):2455-61. doi: 10.1038/leu.2012.123. Epub 2012 May 4. PubMed PMID: 22555150.
51. Resende RG, Correia-Silva JD, Silva TA, Xavier SG, **Bittencourt H**, Gomez RS, Abreu MH. Saliva and blood interferon gamma levels and IFNG genotypes in acute graft-versus-host disease. Oral Dis. 2012 Nov;18(8):816-22. doi: 10.1111/j.1601-0825.2012.01955.x. Epub 2012 Jul 3. PubMed PMID: 22748084.
52. Pimenta Amaral TM, Campos CC, Moreira dos Santos TP, Leles CR, Teixeira AL, Teixeira MM, **Bittencourt H**, Silva TA. Effect of salivary stimulation therapies on salivary flow and chemotherapy-induced mucositis: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 May;113(5):628-37. doi: 10.1016/j.oooo.2011.10.012. Epub 2012 Apr 12. PubMed PMID: 22668621.
53. Resende RG, de Fátima Correia-Silva J, Araújo TC, Brito JA, **Bittencourt H**, Gomez RS, Abreu MH. Oral cGVHD screening tests in the diagnosis of systemic chronic graft-versus-host disease. Clin Oral Investig. 2012 Apr;16(2):565-70. doi: 10.1007/s00784-011-0529-8. Epub 2011 Mar 3. PubMed PMID: 21369795.
54. Correia-Silva JF, Resende RG, Araújo TC, Abreu MH, Teixeira MM, **Bittencourt H**, Silva TA, Gomez RS. HCMV gB genotype and its association with cytokine levels in hematopoietic stem cell transplantation.

Oral Dis. 2011 Jul;17(5):530-7. doi: 10.1111/j.1601-0825.2011.01801.x. Epub 2011 Feb 18. PubMed PMID: 21332604.

55. Marcolino MS, Ribeiro AL, Clementino NC, Nunes Mdo C, Barbosa MM, Silva MH, **Bittencourt H**, Geleijnse ML, Boersma E. The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia. Leuk Res. 2011 Mar;35(3):317-22. doi: 10.1016/j.leukres.2010.07.011. Epub 2010 Aug 6. PubMed PMID: 20692037.
56. Lino VA, Santos SM, **Bittencourt H**, Silva ML, Spizziri T, Bretas R, Neves SP. Quantification of CD8(+)/CD38(+) T lymphocytes by flow cytometry does not represent a good biomarker to monitor the reactivation of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter. 2011;33(4):268-73. doi: 10.5581/1516-8484.20110075. PubMed PMID: 23049317; PubMed Central PMCID: PMC3415765.
57. **Bittencourt H**, Teixeira Junior AL, Glória AB, Ribeiro AF, Fagundes EM. Acute promyelocytic leukemia presenting as an extradural mass. Rev Bras Hematol Hemoter. 2011;33(6):478-80. doi: 10.5581/1516-8484.20110126. PubMed PMID: 23049367; PubMed Central PMCID: PMC3459371.
58. Neuenschwander LC, **Bittencourt H**, Ribeiro AF, Teixeira AL, Teixeira MM, Teixeira JC, Nobre V. Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients. Clinics (Sao Paulo). 2011;66(10):1699-705. PubMed PMID: 22012040; PubMed Central PMCID: PMC3180156.
59. Mancuzo EV, Neves MA, **Bittencourt H**, de Rezende NA. [Non-infectious pulmonary complications after the hematopoietic stem cell transplantation]. Rev Port Pneumol. 2010 Sep-Oct;16(5):815-28. Review. Portuguese. PubMed PMID: 20927497.
60. Resende RG, Correia-Silva Jde F, Arão TC, Silva TA, Abreu MH, **Bittencourt H**, Gomez RS. Investigation of functional IL-10 gene polymorphism and IL-10 levels in acute graft-versus-host disease. J Clin Immunol. 2010 May;30(3):465-73. doi: 10.1007/s10875-010-9377-6. Epub 2010 Mar 2. PubMed PMID: 20195716.
61. Correia-Silva JF, Bruna-Romero O, Resende RG, Miranda LP, Oliveira FE, Costa FO, Xavier SG, Figueiredo-Neves SP, Almeida HC, **Bittencourt H**, Gomez RS. Saliva as a source of HCMV DNA in allogeneic stem cell transplantation patients. Oral Dis. 2010 Mar;16(2):210-6. doi: 10.1111/j.1601-0825.2009.01637.x. PubMed PMID: 20374507.
62. Macedo AV, Freitas IF, Oliveira FB, Resende C, Mendes CU, Vieira AK, Castro LC, Rego EM, Clementino NC, **Bittencourt H**. Granulocytic sarcoma of the stomach: relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2010;3(2):94-8. PubMed PMID: 20543544.
63. Silla L, Fischer GB, Paz A, Daudt LE, Mitto I, Katz B, da Graça Grossini M, **Bittencourt H**, Jochims A, Fogliatto L, Bittar CM, Friedrisch JR, Bittencourt RI. Patient socioeconomic status as a prognostic factor for allo-SCT. Bone Marrow Transplant. 2009 Apr;43(7):571-7. doi: 10.1038/bmt.2008.358. Epub 2008 Nov 3. PubMed PMID: 18978820.
64. Rocha V, Porcher R, Fernandes JF, Filion A, **Bittencourt H**, Silva W Jr, Vilela G, Zanette DL, Ferry C, Larghero J, Devergie A, Ribaud P, Skvortsova Y, Tamouza R, Gluckman E, Socie G, Zago MA. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia. 2009 Mar;23(3):545-56. doi: 10.1038/leu.2008.323. Epub 2008 Nov 13. PubMed PMID: 19005482.

65. Guimaraes AL, Gomes CC, da Silva LM, Correia-Silva Jde F, Victoria JM, Gomez RS, **Bittencourt H**. Association between oral HSV-1 and survival in allogeneic hematopoietic stem cell transplanted patients. Med Oral Patol Oral Cir Bucal. 2009 Feb 1;14(2):E62-8. PubMed PMID: 19179951.
66. **Bittencourt H**, Lopes M, de Macedo AV, Teixeira ER, Gomes GG, Ferreira GG, Amaral L, Soares P, Vieira M, Dusse LM. A retrospective comparison of allogeneic peripheral blood stem cell versus bone marrow transplantation. Hematol Oncol Stem Cell Ther. 2009;2(1):272-7. PubMed PMID: 20063557.
67. Ribeiro AL, Marcolino MS, **Bittencourt H**, Barbosa MM, Nunes Mdo C, Xavier VF, Clementino NC. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008 Dec;32(12):1809-14. doi: 10.1016/j.leukres.2008.03.020. Epub 2008 May 20. PubMed PMID: 18495246.
68. **Bittencourt H**, Funke V, Fogliatto L, Magalhães S, Setubal D, Paz A, Macedo AV, Ruiz J, Azambuja AP, Silla L, Clementino N, Pasquini R. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant. 2008 Nov;42(9):597-600. doi: 10.1038/bmt.2008.218. Epub 2008 Aug 4. PubMed PMID: 18679373.
69. da Gama Torres HO, Vilela EG, da Cunha AS, Goulart EM, Souza MH, Aguirre AC, Azevedo WM, Lodi FM, Silva AA, **Bittencourt H**. Efficacy of glutamine-supplemented parenteral nutrition on short-term survival following allo-SCT: a randomized study. Bone Marrow Transplant. 2008 Jun;41(12):1021-7. doi: 10.1038/bmt.2008.27. Epub 2008 Mar 3. PubMed PMID: 18317456.
70. Jácomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, **Bittencourt H**, Bittencourt RI, Bortolheiro TC, Paton EJ, Bendlin R, Ismael S, Chauffaille Mde L, Silva D, Pagnano KB, Ribeiro R, Rego EM. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007 Oct;92(10):1431-2. PubMed PMID: 18024380.
71. Correia-Silva Jde F, Victória JM, Guimarães AL, Salomão UE, de Abreu MH, **Bittencourt H**, Gomez RS. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients. Oral Dis. 2007 Mar;13(2):163-9. PubMed PMID: 17305617.
72. **Bittencourt H**, Rocha V, Filion A, Ionescu I, Herr AL, Garnier F, Ades L, Esperou H, Devergie A, Ribaud P, Socie G, Gluckman E. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant. 2005 Sep;36(5):431-5. PubMed PMID: 15980881.
73. De Souza CA, Vigorito AC, Ruiz MA, Nucci M, Dulley FL, Funcke V, Tabak D, Azevedo AM, Byington R, Macedo MC, Saboya R, Penteado Aranha FJ, Oliveira GB, Zulli R, Martins Miranda EC, Azevedo WM, Lodi FM, Voltarelli JC, Simões BP, Colturato V, De Souza MP, Silla L, **Bittencourt H**, Piron-Ruiz L, Maiolino A, Gratwohl A, Pasquini R. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome. Haematologica. 2005 Feb;90(2):232-7. PubMed PMID: 15710577.
74. Rocha V, Franco RF, Porcher R, **Bittencourt H**, Silva WA Jr, Latouche A, Devergie A, Esperou H, Ribaud P, Socie G, Zago MA, Gluckman E. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002 Dec 1;100(12):3908-18. Epub 2002 Jul 25. PubMed PMID: 12393699.

75. **Bittencourt H**, Rocha V, Chevret S, Socié G, Espérou H, Devergie A, Dal Cortivo L, Marolleau JP, Garnier F, Ribaud P, Gluckman E. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002 Apr 15;99(8):2726-33. PubMed PMID: 11929759.
76. Fogliatto L, **Bittencourt H**, Nunes AS, Salenave PR, Silva GS, Daudt LE, Job FM, Bittencourt R, Onsten T, Silla LM. Outcome of treatment in adult acute lymphoblastic leukemia in southern Brazil using a modified german multicenter acute lymphoblastic leukemia protocol. Acta Haematol. 2002;107(4):203-7. Review. PubMed PMID: 12053147.
77. Rocha V, Carmagnat MV, Chevret S, Flinois O, **Bittencourt H**, Esperou H, Garnier F, Ribaud P, Devergie A, Socié G, Dal'Cortivo L, Marolleau JP, Charron D, Gluckman E, Rabian C. Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. Exp Hematol. 2001 Nov;29(11):1347-52. PubMed PMID: 11698131.
78. Chen Y, Rocha V, **Bittencourt H**, Scieux C, Loiseau P, Espérou H, Devergie A, Guardiola P, Socié G, Chevret S, Charron D, Gluckman E, Ribaud P. Relationship between HLA alleles and cytomegalovirus infection after allogeneic hematopoietic stem cell transplant. Blood. 2001 Jul 15;98(2):500-1. PubMed PMID: 11455950.
79. Morariu-Zamfir R, Rocha V, Devergie A, Socié G, Ribaud P, Esperou H, Parquet N, Guardiola P, Dal Cortivo L, **Bittencourt H**, Garnier F, Traineau R, Marolleau JP, Chevret S, Gluckman E. Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant. 2001 Mar;27(6):575-80. PubMed PMID: 11319585.
80. Garderet L, **Bittencourt H**, Kaliski A, Daniel M, Ribaud P, Socié G, Gluckman E. Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. Eur J Haematol. 2001 Feb;66(2):137-9. PubMed PMID: 11168523.
81. Garderet L, **Bittencourt H**, Sebe P, Kaliski A, Claisse JP, Espérou H, Ribaud P, Estrade V, Gluckman E, Gattegno B. Cystectomy for severe hemorrhagic cystitis in allogeneic stem cell transplant recipients. Transplantation. 2000 Dec 27;70(12):1807-11. PubMed PMID: 11152115.

Complete list of Pubmed indexed publication at :

https://www.ncbi.nlm.nih.gov/sites/myncbi/1fM_p1w9ISm/bibliography/40124776/public/?sort=date&direction=descending